Journal Article
. 2014 Jun; 31(7):55.
doi: 10.1007/s12032-014-0055-z.

Luminal breast cancer classification according to proliferative indices: clinicopathological characteristics and short-term survival analysis

Yan Sun 1 Gang Nie  Zhimin Wei  Zhidong Lv  Xiaoyi Liu  Haibo Wang  
  • PMID: 24935624
  •     37 References
  •     4 citations


The classification of luminal breast cancer has been a popular topic regarding its heterogeneity with distinct biological features and clinical outcomes. This study aimed to assess the power of proliferative indices (Ki67 and histological grade) to determine various clinicopathological characteristics and survival in luminal disease. A total of 541 patients with stage I-III luminal breast cancer were enrolled. Subtypes were determined using proliferative indices and were compared with clinicopathological variables and short-term survival. The significance of various treatments was evaluated in a subgroup of pN0 (lymph node negative) patients. Histological grade, independent of other variables, was a better predictor in the ER/PR+, human epidermal growth factor receptor 2 (Her-2) subgroup (p = 0.011) and the pN0 subgroup (p = 0.044) compared with Ki67, which only showed significance in the ER/PR+, Her-2 subgroup (p = 0.008). Neither grade nor Ki67 was associated with outcomes in the luminal Her-2 class. In pN0 patients, various treatments did not show significance in short-term survival. Histological grade outperformed Ki67 as a determinant for the stratification of luminal class regarding short-term survival. Chemotherapy most likely did not provide additional benefit to pN0 patients with luminal breast cancer compared with endocrine therapy.

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.
Mohammed A Aleskandarany, Andrew R Green, +5 authors, Emad A Rakha.
Breast Cancer Res, 2012 Jan 10; 14(1). PMID: 22225836    Free PMC article.
The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
P C Clahsen, C J van de Velde, +5 authors, M J van de Vijver.
Eur J Surg Oncol, 1999 Jul 27; 25(4). PMID: 10419704
Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland.
A Spitale, P Mazzola, +2 authors, A Bordoni.
Ann Oncol, 2008 Dec 17; 20(4). PMID: 19074747
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.
E H Lips, L Mulder, +5 authors, J Wesseling.
Breast Cancer Res Treat, 2013 Jul 06; 140(1). PMID: 23828499    Free PMC article.
Is breast cancer the same disease in Asian and Western countries?
Stanley P L Leong, Zhen-Zhou Shen, +7 authors, William D Foulkes.
World J Surg, 2010 Jul 08; 34(10). PMID: 20607258    Free PMC article.
Highly Cited.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Molecular evolution of breast cancer.
Peter T Simpson, Jorge S Reis-Filho, Theodora Gale, Sunil R Lakhani.
J Pathol, 2005 Jan 11; 205(2). PMID: 15641021
Highly Cited. Review.
Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers.
Rohit Bhargava, Joan Striebel, +4 authors, David J Dabbs.
Int J Clin Exp Pathol, 2009 Mar 19; 2(5). PMID: 19294003    Free PMC article.
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
E de Azambuja, F Cardoso, +7 authors, M Paesmans.
Br J Cancer, 2007 Apr 25; 96(10). PMID: 17453008    Free PMC article.
Highly Cited.
Ki67 in breast cancer: prognostic and predictive potential.
Rinat Yerushalmi, Ryan Woods, +2 authors, Karen A Gelmon.
Lancet Oncol, 2010 Feb 16; 11(2). PMID: 20152769
Highly Cited. Review.
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
Pratyaksha Wirapati, Christos Sotiriou, +10 authors, Mauro Delorenzi.
Breast Cancer Res, 2008 Jul 30; 10(4). PMID: 18662380    Free PMC article.
Highly Cited.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
New insight into Ki67 expression at the invasive front in breast cancer.
Peng Gong, Yingxin Wang, +2 authors, Zhongyu Wang.
PLoS One, 2013 Feb 06; 8(1). PMID: 23382998    Free PMC article.
Histological and molecular types of breast cancer: is there a unifying taxonomy?
Britta Weigelt, Jorge S Reis-Filho.
Nat Rev Clin Oncol, 2009 Nov 28; 6(12). PMID: 19942925
Highly Cited. Review.
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.
Britta Weigelt, Frederick L Baehner, Jorge S Reis-Filho.
J Pathol, 2009 Nov 21; 220(2). PMID: 19927298
Highly Cited. Review.
Differences in risk factors for breast cancer molecular subtypes in a population-based study.
Xiaohong R Yang, Mark E Sherman, +15 authors, Montserrat García-Closas.
Cancer Epidemiol Biomarkers Prev, 2007 Mar 21; 16(3). PMID: 17372238
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Breast cancer prognostic classification in the molecular era: the role of histological grade.
Emad A Rakha, Jorge S Reis-Filho, +15 authors, Ian O Ellis.
Breast Cancer Res, 2010 Sep 02; 12(4). PMID: 20804570    Free PMC article.
Highly Cited. Review.
Prognostic value of proliferation in invasive breast cancer: a review.
P J van Diest, E van der Wall, J P A Baak.
J Clin Pathol, 2004 Jun 29; 57(7). PMID: 15220356    Free PMC article.
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?
Helen Trihia, Susan Murray, +8 authors, International Breast Cancer Study Group.
Cancer, 2003 Feb 25; 97(5). PMID: 12599241
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Meredith M Regan, Patrick Neven, +14 authors, International Breast Cancer Study Group (IBCSG).
Lancet Oncol, 2011 Oct 25; 12(12). PMID: 22018631    Free PMC article.
Highly Cited.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, +14 authors, Sibylle Loibl.
J Clin Oncol, 2012 Apr 18; 30(15). PMID: 22508812
Highly Cited.
Gene-expression signatures in breast cancer.
Christos Sotiriou, Lajos Pusztai.
N Engl J Med, 2009 Feb 21; 360(8). PMID: 19228622
Highly Cited. Review.
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype.
Masumi Yanagawa, Kenzo Ikemot, +6 authors, Kohsuke Sasaki.
BMC Res Notes, 2012 Jul 27; 5. PMID: 22830453    Free PMC article.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
High-risk estrogen-receptor-positive breast cancer: identification and implications for therapy.
Rosemary L Balleine, Nicholas R Wilcken.
Mol Diagn Ther, 2012 Jul 21; 16(4). PMID: 22812573
Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer.
M G Daidone, R Silvestrini.
J Natl Cancer Inst Monogr, 2002 Jan 05; (30). PMID: 11773289
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
Aron Goldhirsch, William C Wood, +3 authors, Hans-Jörg Senn.
J Clin Oncol, 2003 Jul 09; 21(17). PMID: 12847142
Highly Cited. Review.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Christine Desmedt, Benjamin Haibe-Kains, +6 authors, Christos Sotiriou.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698033
Highly Cited.
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.
Anna V Ivshina, Joshy George, +12 authors, Lance D Miller.
Cancer Res, 2006 Nov 03; 66(21). PMID: 17079448
Highly Cited.
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
M Colozza, E Azambuja, +3 authors, M J Piccart.
Ann Oncol, 2005 Jun 28; 16(11). PMID: 15980158
Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database.
Carlos S Vallejos, Henry L Gómez, +8 authors, Carlos E Vigil.
Clin Breast Cancer, 2010 Aug 14; 10(4). PMID: 20705562
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Molecular classification of estrogen receptor-positive/luminal breast cancers.
Felipe C Geyer, Daniel N Rodrigues, Britta Weigelt, Jorge S Reis-Filho.
Adv Anat Pathol, 2011 Dec 14; 19(1). PMID: 22156833
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
A Goldhirsch, W C Wood, +4 authors, 10th St. Gallen conference.
Ann Oncol, 2007 Aug 07; 18(7). PMID: 17675394
Highly Cited. Review.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, +14 authors, Robert C Millikan.
JAMA, 2006 Jun 08; 295(21). PMID: 16757721
Highly Cited.
Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Hyun Ae Jung, Yeon Hee Park, +10 authors, Young-Hyuck Im.
Tumour Biol, 2014 Oct 20; 36(2). PMID: 25326808
Aberrant expression of Arpin in human breast cancer and its clinical significance.
Xiangping Liu, Bin Zhao, +6 authors, Zhiqiang Qu.
J Cell Mol Med, 2015 Dec 10; 20(3). PMID: 26648569    Free PMC article.
Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.
Inna Tishchenko, Heloisa Helena Milioli, Carlos Riveros, Pablo Moscato.
PLoS One, 2016 Jun 25; 11(6). PMID: 27341628    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Systematic Review.